|
1
|
Gilligan T, Lin DW, Aggarwal R, Chism D,
Cost N, Derweesh IH, Emamekhoo H, Feldman DR, Geynisman DM, Hancock
SL, et al: Testicular cancer, version 2.2020, NCCN clinical
practice guidelines in oncology. J Natl Compr Canc Netw.
17:1529–1554. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Winter C and Albers P: Testicular germ
cell tumors: Pathogenesis, diagnosis and treatment. Nat Rev
Endocrinol. 7:43–53. 2011.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Caggiano C, Cavallo F, Giannattasio T,
Cappelletti G, Rossi P, Grimaldi P, Feldman DR, Jasin M and Barchi
M: Testicular germ cell tumors acquire cisplatin resistance by
rebalancing the usage of DNA repair pathways. Cancers (Basel).
13(787)2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Shen H, Shih J, Hollern DP, Wang L, Bowlby
R, Tickoo SK, Thorsson V, Mungall AJ, Newton Y, Hegde AM, et al:
Integrated molecular characterization of testicular germ cell
tumors. Cell Rep. 23:3392–3406. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Batool A, Liu XM, Zhang CL, Hao CF, Chen
SR and Liu YX: Recent advances in the regulation of testicular germ
cell tumors by microRNAs. Front Biosci (Landmark Ed). 24:765–776.
2019.PubMed/NCBI View
Article : Google Scholar
|
|
6
|
Batool A, Karimi N, Wu XN, Chen SR and Liu
YX: Testicular germ cell tumor: A comprehensive review. Cell Mol
Life Sci. 76:1713–1727. 2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Fukawa T and Kanayama HO: Current
knowledge of risk factors for testicular germ cell tumors. Int J
Urol. 25:337–344. 2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Voutsadakis IA: The chemosensitivity of
testicular germ cell tumors. Cell Oncol (Dordr). 37:79–94.
2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Brown A, Kumar S and Tchounwou PB:
Cisplatin-based chemotherapy of human cancers. J Cancer Sci Ther.
11(97)2019.PubMed/NCBI
|
|
10
|
de Vries G, Rosas-Plaza X, van Vugt MATM,
Gietema JA and de Jong S: Testicular cancer: Determinants of
cisplatin sensitivity and novel therapeutic opportunities. Cancer
Treat Rev. 88(102054)2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Yang Y, Yang C, Li T, Yu S, Gan T, Hu J,
Cui J and Zheng X: The deubiquitinase USP38 promotes NHEJ repair
through regulation of HDAC1 activity and regulates cancer cell
response to genotoxic insults. Cancer Res. 80:719–731.
2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hoeijmakers JH: DNA damage, aging, and
cancer. N Engl J Med. 361:1475–1485. 2009.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Groelly FJ, Fawkes M, Dagg RA, Blackford
AN and Tarsounas M: Targeting DNA damage response pathways in
cancer. Nat Rev Cancer. 23:78–94. 2023.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Jackson SP and Bartek J: The DNA-damage
response in human biology and disease. Nature. 461:1071–1078.
2009.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Yang D and Wang AH: Structural studies of
interactions between anticancer platinum drugs and DNA. Prog
Biophys Mol Biol. 66:81–111. 1996.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Eastman A: Characterization of the adducts
produced in DNA by cis-diamminedichloroplatinum(II) and
cis-dichloro(ethylenediamine)platinum(II). Biochemistry.
22:3927–3933. 1983.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Jordan P and Carmo-Fonseca M: Molecular
mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci.
57:1229–1235. 2000.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Országhová Z, Kalavska K, Mego M and
Chovanec M: Overcoming chemotherapy resistance in germ cell tumors.
Biomedicines. 10(972)2022.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Welsh C, Day R, McGurk C, Masters JR, Wood
RD and Köberle B: Reduced levels of XPA, ERCC1 and XPF DNA repair
proteins in testis tumor cell lines. Int J Cancer. 110:352–361.
2004.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Usanova S, Piée-Staffa A, Sied U, Thomale
J, Schneider A, Kaina B and Köberle B: Cisplatin sensitivity of
testis tumour cells is due to deficiency in interstrand-crosslink
repair and low ERCC1-XPF expression. Mol Cancer.
9(248)2010.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Mego M, Cierna Z, Svetlovska D, Macak D,
Machalekova K, Miskovska V, Chovanec M, Usakova V, Obertova J,
Babal P and Mardiak J: PARP expression in germ cell tumours. J Clin
Pathol. 66:607–612. 2013.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Cavallo F, Graziani G, Antinozzi C,
Feldman DR, Houldsworth J, Bosl GJ, Chaganti RS, Moynahan ME, Jasin
M and Barchi M: Reduced proficiency in homologous recombination
underlies the high sensitivity of embryonal carcinoma testicular
germ cell tumors to cisplatin and poly (adp-ribose) polymerase
inhibition. PLoS One. 7(e51563)2012.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Gutekunst M, Mueller T, Weilbacher A,
Dengler MA, Bedke J, Kruck S, Oren M, Aulitzky WE and van der Kuip
H: Cisplatin hypersensitivity of testicular germ cell tumors is
determined by high constitutive Noxa levels mediated by Oct-4.
Cancer Res. 73:1460–1469. 2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Koster R, Timmer-Bosscha H, Bischoff R,
Gietema JA and de Jong S: Disruption of the MDM2-p53 interaction
strongly potentiates p53-dependent apoptosis in cisplatin-resistant
human testicular carcinoma cells via the Fas/FasL pathway. Cell
Death Dis. 2(e148)2011.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Spierings DCJ, de Vries EGE, Vellenga E
and de Jong S: Loss of drug-induced activation of the CD95
apoptotic pathway in a cisplatin-resistant testicular germ cell
tumor cell line. Cell Death Differ. 10:808–822. 2003.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Gutekunst M, Oren M, Weilbacher A, Dengler
MA, Markwardt C, Thomale J, Aulitzky WE and van der Kuip H: p53
hypersensitivity is the predominant mechanism of the unique
responsiveness of testicular germ cell tumor (TGCT) cells to
cisplatin. PLoS One. 6(e19198)2011.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Morsi RZ, Hage-Sleiman R, Kobeissy H and
Dbaibo G: Noxa: Role in cancer pathogenesis and treatment. Curr
Cancer Drug Targets. 18:914–928. 2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Schmidtova S, Kalavska K and Kucerova L:
Molecular mechanisms of cisplatin chemoresistance and its
circumventing in testicular germ cell tumors. Curr Oncol Rep.
20(88)2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Woldu SL, Amatruda JF and Bagrodia A:
Testicular germ cell tumor genomics. Curr Opin Urol. 27:41–47.
2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Lobo J, Alzamora MA, Guimarães R, Cantante
M, Lopes P, Braga I, Maurício J, Jerónimo C and Henrique R: p53 and
MDM2 expression in primary and metastatic testicular germ cell
tumors: Association with clinical outcome. Andrology. 8:1233–1242.
2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Han MH, Park SW, Do HJ, Chung HJ, Song H
and Kim JH, Kim NH, Park KH and Kim JH: Growth and differentiation
factor 3 is transcriptionally regulated by OCT4 in human embryonic
carcinoma cells. Biol Pharm Bull. 39:1802–1808. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Cheng CJ, Wu YC, Shu JA, Ling TY, Kuo HC,
Wu JY, Chang EE, Chang SC and Huang YH: Aberrant expression and
distribution of the OCT-4 transcription factor in seminomas. J
Biomed Sci. 14:797–807. 2007.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Mohiuddin IS, Wei SJ and Kang MH: Role of
OCT4 in cancer stem-like cells and chemotherapy resistance. Biochim
Biophys Acta Mol Basis Dis. 1866(165432)2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Wu YC, Ling TY, Lu SH, Kuo HC, Ho HN, Yeh
SD, Shen CN and Huang YH: Chemotherapeutic sensitivity of
testicular germ cell tumors under hypoxic conditions is negatively
regulated by SENP1-controlled sumoylation of OCT4. Cancer Res.
72:4963–4973. 2012.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Li L, Xu M, Li X, Lv C, Zhang X, Yu H,
Zhang M, Fu Y, Meng H and Zhou J: Platelet-derived growth factor-B
(PDGF-B) induced by hypoxia promotes the survival of pulmonary
arterial endothelial cells through the PI3K/Akt/Stat3 pathway. Cell
Physiol Biochem. 35:441–451. 2015.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Pullamsetti SS, Berghausen EM, Dabral S,
Tretyn A, Butrous E, Savai R, Butrous G, Dahal BK, Brandes RP,
Ghofrani HA, et al: Role of Src tyrosine kinases in experimental
pulmonary hypertension. Arterioscler Thromb Vasc Biol.
32:1354–1365. 2012.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Noskovičová N, Petřek M, Eickelberg O and
Heinzelmann K: Platelet-derived growth factor signaling in the
lung. From lung development and disease to clinical studies. Am J
Respir Cell Mol Biol. 52:263–284. 2015.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Rieg AD, Suleiman S, Anker C, Verjans E,
Rossaint R, Uhlig S and Martin C: PDGF-BB regulates the pulmonary
vascular tone: Impact of prostaglandins, calcium, MAPK- and
PI3K/AKT/mTOR signalling and actin polymerisation in pulmonary
veins of guinea pigs. Respir Res. 19(120)2018.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Liu P, Cheng H, Roberts TM and Zhao JJ:
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev
Drug Discov. 8:627–644. 2009.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Zhao L and Vogt PK: Class I PI3K in
oncogenic cellular transformation. Oncogene. 27:5486–5496.
2008.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Fruman DA, Chiu H, Hopkins BD, Bagrodia S,
Cantley LC and Abraham RT: The PI3K pathway in human disease. Cell.
170:605–635. 2017.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Papa A and Pandolfi PP: The PTEN-PI3K axis
in cancer. Biomolecules. 9(153)2019.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Di Vizio D, Cito L, Boccia A, Chieffi P,
Insabato L, Pettinato G, Motti ML, Schepis F, D'Amico W, Fabiani F,
et al: Loss of the tumor suppressor gene PTEN marks the transition
from intratubular germ cell neoplasias (ITGCN) to invasive germ
cell tumors. Oncogene. 24:1882–1894. 2005.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Juliachs M, Muñoz C, Moutinho CA, Vidal A,
Condom E, Esteller M, Graupera M, Casanovas O, Germà JR, Villanueva
A and Viñals F: The PDGFRβ-AKT pathway contributes to CDDP-acquired
resistance in testicular germ cell tumors. Clin Cancer Res.
20:658–667. 2014.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Koster R, di Pietro A, Timmer-Bosscha H,
Gibcus JH, van den Berg A, Suurmeijer AJ, Bischoff R, Gietema JA
and de Jong S: Cytoplasmic p21 expression levels determine
cisplatin resistance in human testicular cancer. J Clin Invest.
120:3594–3605. 2010.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Zhang X, Tang N, Hadden TJ and Rishi AK:
Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta.
1813:1978–1986. 2011.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Selfe J, Goddard NC, McIntyre A, Taylor
KR, Renshaw J, Popov SD, Thway K, Summersgill B, Huddart RA,
Gilbert DC and Shipley JM: IGF1R signalling in testicular germ cell
tumour cells impacts on cell survival and acquired cisplatin
resistance. J Pathol. 244:242–253. 2018.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Gilbert D, Rapley E and Shipley J:
Testicular germ cell tumours: Predisposition genes and the male
germ cell niche. Nat Rev Cancer. 11:278–288. 2011.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Selfe J and Shipley JM: IGF signalling in
germ cells and testicular germ cell tumours: Roles and therapeutic
approaches. Andrology. 7:536–544. 2019.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Schneeweiss-Gleixner M, Byrgazov K,
Stefanzl G, Berger D, Eisenwort G, Lucini CB, Herndlhofer S,
Preuner S, Obrova K, Pusic P, et al: CDK4/CDK6 inhibition as a
novel strategy to suppress the growth and survival of
BCR-ABL1T315I+ clones in TKI-resistant CML.
EBioMedicine. 50:111–121. 2019.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Rossini E, Bosatta V, Abate A, Fragni M,
Salvi V, Basnet RM, Zizioli D, Bosisio D, Piovani G, Valcamonico F,
et al: Cisplatin cytotoxicity in human testicular germ cell tumor
cell lines is enhanced by the CDK4/6 inhibitor palbociclib. Clin
Genitourin Cancer. 19:316–324. 2021.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Mayer F, Stoop H, Scheffer GL, Scheper R,
Oosterhuis JW, Looijenga LH and Bokemeyer C: Molecular determinants
of treatment response in human germ cell tumors. Clin Cancer Res.
9:767–773. 2003.PubMed/NCBI
|
|
53
|
Jacobsen C and Honecker F: Cisplatin
resistance in germ cell tumours: Models and mechanisms. Andrology.
3:111–121. 2015.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Oosterhuis JW and Looijenga LHJ: Human
germ cell tumours from a developmental perspective. Nat Rev Cancer.
19:522–537. 2019.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Sonnenburg D, Spinella MJ and Albany C:
Epigenetic targeting of platinum resistant testicular cancer. Curr
Cancer Drug Targets. 16:789–795. 2016.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Fazal Z, Singh R, Fang F, Bikorimana E,
Baldwin H, Corbet A, Tomlin M, Yerby C, Adra N, Albany C, et al:
Hypermethylation and global remodelling of DNA methylation is
associated with acquired cisplatin resistance in testicular germ
cell tumours. Epigenetics. 16:1071–1084. 2021.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Liu ZX, Li LM, Sun HL and Liu SM: Link
between m6A modification and cancers. Front Bioeng Biotechnol.
6(89)2018.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Miranda-Gonçalves V, Lobo J,
Guimarães-Teixeira C, Barros-Silva D, Guimarães R, Cantante M,
Braga I, Maurício J, Oing C, Honecker F, et al: The component of
the m6A writer complex VIRMA is implicated in aggressive
tumor phenotype, DNA damage response and cisplatin resistance in
germ cell tumors. J Exp Clin Cancer Res. 40(268)2021.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Wei J, Yin Y, Zhou J, Chen H, Peng J, Yang
J and Tang Y: METTL3 potentiates resistance to cisplatin through
m6A modification of TFAP2C in seminoma. J Cell Mol Med.
24:11366–11380. 2020.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Doghish AS, Moustafa HAM, Elballal MS,
Sallam AM, El-Dakroury WA, Abdel Mageed SS, Elesawy AE,
Abdelmaksoud NM, Shahin RK, Midan HM, et al: The potential role of
miRNAs in the pathogenesis of testicular germ cell tumors-A Focus
on signaling pathways interplay. Pathol Res Pract.
248(154611)2023.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Sawant A, Floyd AM, Dangeti M, Lei W,
Sobol RW and Patrick SM: Differential role of base excision repair
proteins in mediating cisplatin cytotoxicity. DNA Repair (Amst).
51:46–59. 2017.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Cavallo F, Caggiano C, Jasin M and Barchi
M: Assessing homologous recombination and interstrand cross-link
repair in embryonal carcinoma testicular germ cell tumor cell
lines. Methods Mol Biol. 2195:113–123. 2021.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Pannunzio NR, Watanabe G and Lieber MR:
Nonhomologous DNA end-joining for repair of DNA double-strand
breaks. J Biol Chem. 293:10512–10523. 2018.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Scully R, Panday A, Elango R and Willis
NA: DNA double-strand break repair-pathway choice in somatic
mammalian cells. Nat Rev Mol Cell Biol. 20:698–714. 2019.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Chang HHY, Pannunzio NR, Adachi N and
Lieber MR: Non-homologous DNA end joining and alternative pathways
to double-strand break repair. Nat Rev Mol Cell Biol. 18:495–506.
2017.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Sugitani N, Sivley RM, Perry KE, Capra JA
and Chazin WJ: XPA: A key scaffold for human nucleotide excision
repair. DNA Repair (Amst). 44:123–135. 2016.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Cierna Z, Miskovska V, Roska J,
Jurkovicova D, Pulzova LB, Sestakova Z, Hurbanova L, Machalekova K,
Chovanec M, Rejlekova K, et al: Increased levels of XPA might be
the basis of cisplatin resistance in germ cell tumours. BMC Cancer.
20(17)2020.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Clairmont CS and D'Andrea AD: REV7 directs
DNA repair pathway choice. Trends Cell Biol. 31:965–978.
2021.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Dash RC and Hadden K: Protein-protein
interactions in translesion synthesis. Molecules.
26(5544)2021.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Shimada Y, Kato T, Sakurai Y, Watanabe H,
Nonaka M, Nanaura N, Ichinoe M and Murakumo Y: Identification of
the promoter region regulating the transcription of the REV7 gene.
Biochem Biophys Res Commun. 662:8–17. 2023.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Sakurai Y, Ichinoe M, Yoshida K, Nakazato
Y, Saito S, Satoh M, Nakada N, Sanoyama I, Umezawa A, Numata Y, et
al: Inactivation of REV7 enhances chemosensitivity and overcomes
acquired chemoresistance in testicular germ cell tumors. Cancer
Lett. 489:100–110. 2020.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Funke K, Einsfelder U, Hansen A, Arévalo
L, Schneider S, Nettersheim D, Stein V and Schorle H: Genome-scale
CRISPR screen reveals neddylation to contribute to cisplatin
resistance of testicular germ cell tumours. Br J Cancer.
128:2270–2282. 2023.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Hinz S, Magheli A, Weikert S, Schulze W,
Krause H, Schrader M, Miller K and Kempkensteffen C: Deregulation
of EZH2 expression in human spermatogenic disorders and testicular
germ cell tumors. World J Urol. 28:631–635. 2010.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Yamagishi M and Uchimaru K: Targeting EZH2
in cancer therapy. Curr Opin Oncol. 29:375–381. 2017.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Sun S, Zhao S, Yang Q, Wang W, Cai E, Wen
Y, Yu L, Wang Z and Cai J: Enhancer of zeste homolog 2 promotes
cisplatin resistance by reducing cellular platinum accumulation.
Cancer Sci. 109:1853–1864. 2018.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Dou D, Ge X, Wang X, Xu X, Zhang Z, Seng
J, Cao Z, Gu Y and Han M: EZH2 contributes to cisplatin resistance
in breast cancer by epigenetically suppressing miR-381 expression.
Onco Targets Ther. 12:9627–9637. 2019.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Xu C, Hao K, Hu H, Sheng Z, Yan J, Wang Q
and Yu L: Expression of the enhancer of zeste homolog 2 in biopsy
specimen predicts chemoresistance and survival in advanced
non-small cell lung cancer receiving first-line platinum-based
chemotherapy. Lung Cancer. 86:268–273. 2014.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Singh R, Fazal Z, Corbet AK, Bikorimana E,
Rodriguez JC, Khan EM, Shahid K, Freemantle SJ and Spinella MJ:
Epigenetic remodeling through downregulation of polycomb repressive
complex 2 mediates chemotherapy resistance in testicular germ cell
tumors. Cancers (Basel). 11(796)2019.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Samaržija I, Tomljanović M, Novak
Kujundžić R and Trošelj KG: EZH2 inhibition and cisplatin as a
combination anticancer therapy: An overview of preclinical studies.
Cancers (Basel). 14(4761)2022.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Singh R, Fazal Z, Bikorimana E, Boyd RI,
Yerby C, Tomlin M, Baldwin H, Shokry D, Corbet AK, Shahid K, et al:
Reciprocal epigenetic remodeling controls testicular cancer
hypersensitivity to hypomethylating agents and chemotherapy. Mol
Oncol. 16:683–698. 2022.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Timmerman DM, Eleveld TF, Sriram S,
Dorssers LCJ, Gillis AJM, Schmidtova S, Kalavska K, van de Werken
HJG, Oing C, Honecker F, et al: Chromosome 3p25.3 gain is
associated with cisplatin resistance and is an independent
predictor of poor outcome in male malignant germ cell tumors. J
Clin Oncol. 40:3077–3087. 2022.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Yu H: Structural activation of Mad2 in the
mitotic spindle checkpoint: The two-state Mad2 model versus the
Mad2 template model. J Cell Biol. 173:153–157. 2006.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Henriques AC, Silva PMA, Sarmento B and
Bousbaa H: The Mad2-binding protein p31comet as a
potential target for human cancer therapy. Curr Cancer Drug
Targets. 21:401–415. 2021.PubMed/NCBI View Article : Google Scholar
|
|
84
|
López-Saavedra A, Ramírez-Otero M,
Díaz-Chávez J, Cáceres-Gutiérrez R, Justo-Garrido M, Andonegui MA,
Mendoza J, Downie-Ruíz Á, Cortés-González C, Reynoso N, et al:
MAD2γ, a novel MAD2 isoform, reduces mitotic arrest and is
associated with resistance in testicular germ cell tumors. Cell
Cycle. 15:2066–2076. 2016.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Kitayama S, Ikeda K, Sato W, Takeshita H,
Kawakami S, Inoue S and Horie K: Testis-expressed gene 11 inhibits
cisplatin-induced DNA damage and contributes to chemoresistance in
testicular germ cell tumor. Sci Rep. 12(18423)2022.PubMed/NCBI View Article : Google Scholar
|
|
86
|
McHugh DJ, Gleeson JP and Feldman DR:
Testicular cancer in 2023: Current status and recent progress. CA
Cancer J Clin. 74:167–186. 2024.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Paffenholz P, Pfister D and Heidenreich A:
Testis-preserving strategies in testicular germ cell tumors and
germ cell neoplasia in situ. Transl Androl Urol. 9 (Suppl
1):S24–S30. 2020.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Chang MM, Pan BS, Wang CY and Huang BM:
Cordycepin-induced unfolded protein response-dependent cell death,
and AKT/MAPK-mediated drug resistance in mouse testicular tumor
cells. Cancer Med. 8:3949–3964. 2019.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Hu Z, Yu J, Gui G, Chen Y, Huang R, Jiang
L, Kwong JSW, Li Y and Zhang L: Cisplatin for testicular germ cell
tumors: A rapid review. J Evid Based Med. 9:144–151.
2016.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Chovanec M, Hanna N, Cary KC, Einhorn L
and Albany C: Management of stage I testicular germ cell tumours.
Nat Rev Urol. 13:663–673. 2016.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Sadek KM, AbdEllatief HY, Mahmoud SFE,
Alexiou A, Papadakis M, Al-Hajeili M, Saad HM and Batiha GE: New
insights on testicular cancer prevalence with novel diagnostic
biomarkers and therapeutic approaches. Cancer Rep (Hoboken).
7(e2052)2024.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Curreri SA, Fung C and Beard CJ: Secondary
malignant neoplasms in testicular cancer survivors. Urol Oncol.
33:392–398. 2015.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Beitzen-Heineke A, Rolling CC, Seidel C,
Erley J, Molwitz I, Muellerleile K, Saering D, Senftinger J,
Börschel N, Engel NW, et al: Long-term cardiotoxicity in germ cell
cancer survivors after platinum-based chemotherapy: Cardiac MR
shows impaired systolic function and tissue alterations. Eur
Radiol. 34:4102–4112. 2024.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Chovanec M, Abu Zaid M, Hanna N, El-Kouri
N, Einhorn LH and Albany C: Long-term toxicity of cisplatin in
germ-cell tumor survivors. Ann Oncol. 28:2670–2679. 2017.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Porcu P, Bhatia S, Sharma M and Einhorn
LH: Results of treatment after relapse from high-dose chemotherapy
in germ cell tumors. J Clin Oncol. 18:1181–1186. 2000.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Chieffi P, De Martino M and Esposito F:
Further insights into testicular germ cell tumor oncogenesis:
Potential therapeutic targets. Expert Rev Anticancer Ther.
20:189–195. 2020.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Einhorn LH, Williams SD, Chamness A,
Brames MJ, Perkins SM and Abonour R: High-dose chemotherapy and
stem-cell rescue for metastatic germ-cell tumors. N Engl J Med.
357:340–348. 2007.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Lorch A, Bascoul-Mollevi C, Kramar A,
Einhorn L, Necchi A, Massard C, De Giorgi U, Fléchon A, Margolin K,
Lotz JP, et al: Conventional-dose versus high-dose chemotherapy as
first salvage treatment in male patients with metastatic germ cell
tumors: Evidence from a large international database. J Clin Oncol.
29:2178–2184. 2011.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Nichols CR, Tricot G, Williams SD, van
Besien K, Loehrer PJ, Roth BJ, Akard L, Hoffman R, Goulet R, Wolff
SN, et al: Dose-intensive chemotherapy in refractory germ cell
cancer-a phase I/II trial of high-dose carboplatin and etoposide
with autologous bone marrow transplantation. J Clin Oncol.
7:932–939. 1989.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Su X, Wang Z, Li L, Zheng M, Zheng C, Gong
P, Zhao P, Ma Y, Tao Q and Cai L: Lipid-polymer nanoparticles
encapsulating doxorubicin and 2'-deoxy-5-azacytidine enhance the
sensitivity of cancer cells to chemical therapeutics. Mol Pharm.
10:1901–1909. 2013.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Ohtani H, Ørskov AD, Helbo AS, Gillberg L,
Liu M, Zhou W, Ungerstedt J, Hellström-Lindberg E, Sun W, Liang G,
et al: Activation of a subset of evolutionarily young transposable
elements and innate immunity are linked to clinical responses to
5-azacytidine. Cancer Res. 80:2441–2450. 2020.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Stahl M, Kohrman N, Gore SD, Kim TK,
Zeidan AM and Prebet T: Epigenetics in cancer: A hematological
perspective. PLoS Genet. 12(e1006193)2016.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Lobo J, Guimarães-Teixeira C, Barros-Silva
D, Miranda-Gonçalves V, Camilo V, Guimarães R, Cantante M, Braga I,
Maurício J, Oing C, et al: Efficacy of HDAC inhibitors belinostat
and panobinostat against cisplatin-sensitive and
cisplatin-resistant testicular germ cell tumors. Cancers (Basel).
12(2903)2020.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Cardoso AR, Lobo J, Miranda-Gonçalves V,
Henrique R and Jerónimo C: Epigenetic alterations as therapeutic
targets in testicular germ cell tumours: Current and future
application of ‘epidrugs’. Epigenetics. 16:353–372. 2021.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Lobo J, Cardoso AR, Miranda-Gonçalves V,
Looijenga LHJ, Lopez M, Arimondo PB, Henrique R and Jerónimo C:
Targeting germ cell tumors with the newly synthesized
flavanone-derived compound MLo1302 efficiently reduces tumor cell
viability and induces apoptosis and cell cycle arrest.
Pharmaceutics. 13(73)2021.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Albany C, Hever-Jardine MP, von Herrmann
KM, Yim CY, Tam J, Warzecha JM, Shin L, Bock SE, Curran BS,
Chaudhry AS, et al: Refractory testicular germ cell tumors are
highly sensitive to the second generation DNA methylation inhibitor
guadecitabine. Oncotarget. 8:2949–2959. 2017.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Oing C, Verem I, Mansour WY, Bokemeyer C,
Dyshlovoy S and Honecker F: 5-Azacitidine exerts prolonged
pro-apoptotic effects and overcomes cisplatin-resistance in
non-seminomatous germ cell tumor cells. Int J Mol Sci.
20(21)2018.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Jostes S, Nettersheim D, Fellermeyer M,
Schneider S, Hafezi F, Honecker F, Schumacher V, Geyer M,
Kristiansen G and Schorle H: The bromodomain inhibitor JQ1 triggers
growth arrest and apoptosis in testicular germ cell tumours in
vitro and in vivo. J Cell Mol Med. 21:1300–1314. 2017.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Zhou W, Chen H, Hong X, Niu X and Lu Q:
Knockdown of DNA methyltransferase-1 inhibits proliferation and
derepresses tumor suppressor genes in myeloma cells. Oncol Lett.
8:2130–2134. 2014.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Tulsyan S, Aftab M, Sisodiya S, Khan A,
Chikara A, Tanwar P and Hussain S: Molecular basis of epigenetic
regulation in cancer diagnosis and treatment. Front Genet.
13(885635)2022.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Lecomte S, Demay F, Ferrière F and Pakdel
F: Phytochemicals targeting estrogen receptors: Beneficial rather
than adverse effects? Int J Mol Sci. 18(1381)2017.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Van Neste L, Bigley J, Toll A, Otto G,
Clark J, Delrée P, Van Criekinge W and Epstein JI: A tissue
biopsy-based epigenetic multiplex PCR assay for prostate cancer
detection. BMC Urol. 12(16)2012.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Jin B and Robertson KD: DNA
methyltransferases, DNA damage repair, and cancer. Adv Exp Med
Biol. 754:3–29. 2013.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Stresemann C and Lyko F: Modes of action
of the DNA methyltransferase inhibitors azacytidine and decitabine.
Int J Cancer. 123:8–13. 2008.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Hollenbach PW, Nguyen AN, Brady H,
Williams M, Ning Y, Richard N, Krushel L, Aukerman SL, Heise C and
MacBeth KJ: A comparison of azacitidine and decitabine activities
in acute myeloid leukemia cell lines. PLoS One.
5(e9001)2010.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Wermann H, Stoop H, Gillis AJM, Honecker
F, van Gurp RJ, Ammerpohl O, Richter J, Oosterhuis JW, Bokemeyer C
and Looijenga LH: Global DNA methylation in fetal human germ cells
and germ cell tumours: Association with differentiation and
cisplatin resistance. J Pathol. 221:433–442. 2010.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Rüter B, Wijermans PW and Lübbert M: DNA
methylation as a therapeutic target in hematologic disorders:
Recent results in older patients with myelodysplasia and acute
myeloid leukemia. Int J Hematol. 80:128–135. 2004.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Beyrouthy MJ, Garner KM, Hever MP,
Freemantle SJ, Eastman A, Dmitrovsky E and Spinella MJ: High DNA
methyltransferase 3B expression mediates 5-aza-deoxycytidine
hypersensitivity in testicular germ cell tumors. Cancer Res.
69:9360–9366. 2009.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Issa JJ, Roboz G, Rizzieri D, Jabbour E,
Stock W, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, et al:
Safety and tolerability of guadecitabine (SGI-110) in patients with
myelodysplastic syndrome and acute myeloid leukaemia: A
multicentre, randomised, dose-escalation phase 1 study. Lancet
Oncol. 16:1099–1110. 2015.PubMed/NCBI View Article : Google Scholar
|
|
120
|
Albany C, Fazal Z, Singh R, Bikorimana E,
Adra N, Hanna NH, Einhorn LH, Perkins SM, Sandusky GE, Christensen
BC, et al: A phase 1 study of combined guadecitabine and cisplatin
in platinum refractory germ cell cancer. Cancer Med. 10:156–163.
2021.PubMed/NCBI View Article : Google Scholar
|
|
121
|
Kurz L, Miklyaeva A, Skowron MA, Overbeck
N, Poschmann G, Becker T, Eul K, Kurz T, Schönberger S, Calaminus
G, et al: ARID1A regulates transcription and the epigenetic
landscape via POLE and DMAP1 while ARID1A deficiency or
pharmacological inhibition sensitizes germ cell tumor cells to ATR
inhibition. Cancers (Basel). 12(905)2020.PubMed/NCBI View Article : Google Scholar
|
|
122
|
Steinemann G, Dittmer A, Kuzyniak W,
Hoffmann B, Schrader M, Schobert R, Biersack B, Nitzsche B and
Höpfner M: Animacroxam, a novel dual-mode compound targeting
histone deacetylases and cytoskeletal integrity of testicular germ
cell cancer cells. Mol Cancer Ther. 16:2364–2374. 2017.PubMed/NCBI View Article : Google Scholar
|
|
123
|
Steinemann G, Dittmer A, Schmidt J,
Josuttis D, Fähling M, Biersack B, Beindorff N, Jolante Koziolek E,
Schobert R, Brenner W, et al: Antitumor and antiangiogenic activity
of the novel chimeric inhibitor animacroxam in testicular germ cell
cancer. Mol Oncol. 13:2679–2696. 2019.PubMed/NCBI View Article : Google Scholar
|
|
124
|
Nettersheim D, Berger D, Jostes S, Skowron
M and Schorle H: Deciphering the molecular effects of romidepsin on
germ cell tumours: DHRS2 is involved in cell cycle arrest but not
apoptosis or induction of romidepsin effectors. J Cell Mol Med.
23:670–679. 2019.PubMed/NCBI View Article : Google Scholar
|
|
125
|
Delmore JE, Issa GC, Lemieux ME, Rahl PB,
Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, et
al: BET bromodomain inhibition as a therapeutic strategy to target
c-Myc. Cell. 146:904–917. 2011.PubMed/NCBI View Article : Google Scholar
|
|
126
|
Burmeister A, Stephan A, Alves Avelar LA,
Müller MR, Seiwert A, Höfmann S, Fischer F, Torres-Gomez H,
Hoffmann MJ, Niegisch G, et al: Establishment and evaluation of
dual HDAC/BET inhibitors as therapeutic options for germ cell
tumors and other urological malignancies. Mol Cancer Ther.
21:1674–1688. 2022.PubMed/NCBI View Article : Google Scholar
|
|
127
|
Lengert AVH, Pereira LDNB, Cabral ERM,
Gomes INF, Jesus LM, Gonçalves MFS, Rocha AOD, Tassinari TA, Silva
LSD, Laus AC, et al: Potential new therapeutic approaches for
cisplatin-resistant testicular germ cell tumors. Front Biosci
(Landmark Ed). 27(245)2022.PubMed/NCBI View Article : Google Scholar
|
|
128
|
Huang TT, Nijman SMB, Mirchandani KD,
Galardy PJ, Cohn MA, Haas W, Gygi SP, Ploegh HL, Bernards R and
D'Andrea AD: Regulation of monoubiquitinated PCNA by DUB
autocleavage. Nat Cell Biol. 8:339–347. 2006.PubMed/NCBI View Article : Google Scholar
|
|
129
|
Hasibeder A, Venkataramani V, Thelen P,
Radzun HJ and Schweyer S: Phytoestrogens regulate the proliferation
and expression of stem cell factors in cell lines of malignant
testicular germ cell tumors. Int J Oncol. 43:1385–1394.
2013.PubMed/NCBI View Article : Google Scholar
|
|
130
|
Kalavska K, Schmidtova S, Chovanec M and
Mego M: Immunotherapy in testicular germ cell tumors. Front Oncol.
10(573977)2020.PubMed/NCBI View Article : Google Scholar
|
|
131
|
Vincent AJ, Ren S, Harris LG, Devine DJ,
Samant RS, Fodstad O and Shevde LA: Cytoplasmic translocation of
p21 mediates NUPR1-induced chemoresistance: NUPR1 and p21 in
chemoresistance. FEBS Lett. 586:3429–3434. 2012.PubMed/NCBI View Article : Google Scholar
|
|
132
|
Xia X, Ma Q, Li X, Ji T, Chen P, Xu H, Li
K, Fang Y, Weng D, Weng Y, et al: Cytoplasmic p21 is a potential
predictor for cisplatin sensitivity in ovarian cancer. BMC Cancer.
11(399)2011.PubMed/NCBI View Article : Google Scholar
|
|
133
|
Wang X, Wang Y, Gou S and Chen F: A
trifunctional Pt(II) complex alleviates the NHEJ/HR-related DSBs
repairs to evade cisplatin-resistance in NSCLC. Bioorg Chem.
104(104210)2020.PubMed/NCBI View Article : Google Scholar
|
|
134
|
Costa A, Forte IM, Pentimalli F, Iannuzzi
CA, Alfano L, Capone F, Camerlingo R, Calabrese A, von Arx C, Benot
Dominguez R, et al: Pharmacological inhibition of CDK4/6 impairs
diffuse pleural mesothelioma 3D spheroid growth and reduces
viability of cisplatin-resistant cells. Front Oncol.
14(1418951)2024.PubMed/NCBI View Article : Google Scholar
|
|
135
|
Romano FJ, Rossetti S, Conteduca V,
Schepisi G, Cavaliere C, Di Franco R, La Mantia E, Castaldo L,
Nocerino F, Ametrano G, et al: Role of DNA repair machinery and p53
in the testicular germ cell cancer: A review. Oncotarget.
7:85641–85649. 2016.PubMed/NCBI View Article : Google Scholar
|
|
136
|
Spierings DC, de Vries EG, Stel AJ, te
Rietstap N, Vellenga E and de Jong S: Low p21Waf1/Cip1 protein
level sensitizes testicular germ cell tumor cells to Fas-mediated
apoptosis. Oncogene. 23:4862–4872. 2004.PubMed/NCBI View Article : Google Scholar
|
|
137
|
Tomida J, Takata KI, Bhetawal S, Person
MD, Chao HP, Tang DG and Wood RD: FAM35A associates with REV7 and
modulates DNA damage responses of normal and BRCA1-defective cells.
EMBO J. 37(e99543)2018.PubMed/NCBI View Article : Google Scholar
|
|
138
|
Lind GE, Skotheim RI, Fraga MF, Abeler VM,
Esteller M and Lothe RA: Novel epigenetically deregulated genes in
testicular cancer include homeobox genes and SCGB3A1 (HIN-1). J
Pathol. 210:441–449. 2006.PubMed/NCBI View Article : Google Scholar
|
|
139
|
Roška J, Wachsmannová L, Hurbanová L,
Šestáková Z, Mueller T, Jurkovičová D and Chovanec M: Differential
gene expression in cisplatin-resistant and -sensitive testicular
germ cell tumor cell lines. Oncotarget. 11:4735–4753.
2020.PubMed/NCBI View Article : Google Scholar
|
|
140
|
Schmidtova S, Dorssers LCJ, Kalavska K,
Gillis AJM, Oosterhuis JW, Stoop H, Miklikova S, Kozovska Z,
Burikova M, Gercakova K, et al: Napabucasin overcomes cisplatin
resistance in ovarian germ cell tumor-derived cell line by
inhibiting cancer stemness. Cancer Cell Int. 20(364)2020.PubMed/NCBI View Article : Google Scholar
|
|
141
|
Schmidtova S, Kalavska K, Gercakova K,
Cierna Z, Miklikova S, Smolkova B, Buocikova V, Miskovska V,
Durinikova E, Burikova M, et al: Disulfiram overcomes cisplatin
resistance in human embryonal carcinoma cells. Cancers (Basel).
11(1224)2019.PubMed/NCBI View Article : Google Scholar
|
|
142
|
Ma H, Cao W and Ding M: MicroRNA-31
weakens cisplatin resistance of medulloblastoma cells via NF-κB and
PI3K/AKT pathways. Biofactors. 46:831–838. 2020.PubMed/NCBI View Article : Google Scholar
|
|
143
|
Luo H, Yi T, Huang D, Chen X, Li X, Wan Q,
Huang H, Huang H, Wei H, Song Y, et al: circ_PTN contributes to
-cisplatin resistance in glioblastoma via PI3K/AKT signaling
through the miR-542-3p/PIK3R3 pathway. Mol Ther Nucleic Acids.
26:1255–1269. 2021.PubMed/NCBI View Article : Google Scholar
|
|
144
|
Fankhauser CD, Curioni-Fontecedro A,
Allmann V, Beyer J, Tischler V, Sulser T, Moch H and Bode PK:
Frequent PD-L1 expression in testicular germ cell tumors. Br J
Cancer. 113:411–413. 2015.PubMed/NCBI View Article : Google Scholar
|
|
145
|
Hong W, Xue M, Jiang J, Zhang Y and Gao X:
Circular RNA circ-CPA4/let-7 miRNA/PD-L1 axis regulates cell
growth, stemness, drug resistance and immune evasion in non-small
cell lung cancer (NSCLC). J Exp Clin Cancer Res.
39(149)2020.PubMed/NCBI View Article : Google Scholar
|
|
146
|
De S, Holvey-Bates EG, Mahen K, Willard B
and Stark GR: The ubiquitin E3 ligase FBXO22 degrades PD-L1 and
sensitizes cancer cells to DNA damage. Proc Natl Acad Sci USA.
118(e2112674118)2021.PubMed/NCBI View Article : Google Scholar
|
|
147
|
Liu L, Lian J, Zhang H, Tian H, Liang M,
Yin M and Sun F: MicroRNA-302a sensitizes testicular embryonal
carcinoma cells to cisplatin-induced cell death. J Cell Physiol.
228:2294–2304. 2013.PubMed/NCBI View Article : Google Scholar
|
|
148
|
Wei J, Gan Y, Peng D, Jiang X, Kitazawa R,
Xiang Y, Dai Y, Tang Y and Yang J: Long non-coding RNA H19 promotes
TDRG1 expression and cisplatin resistance by sequestering
miRNA-106b-5p in seminoma. Cancer Med. 7:6247–6257. 2018.PubMed/NCBI View Article : Google Scholar
|
|
149
|
Huang H, Tian H, Duan Z, Cao Y, Zhang XS
and Sun F: microRNA-383 impairs phosphorylation of H2AX by
targeting PNUTS and inducing cell cycle arrest in testicular
embryonal carcinoma cells. Cell Signal. 26:903–911. 2014.PubMed/NCBI View Article : Google Scholar
|
|
150
|
Elesawy AE, Abulsoud AI, Moustafa HAM,
Elballal MS, Sallam AM, Elazazy O, El-Dakroury WA, Abdel Mageed SS,
Abdelmaksoud NM, Midan HM, et al: miRNAs orchestration of
testicular germ cell tumors-particular emphasis on diagnosis,
progression and drug resistance. Pathol Res Pract.
248(154612)2023.PubMed/NCBI View Article : Google Scholar
|
|
151
|
Özata DM, Li X, Lee L, Liu J, Warsito D,
Hajeri P, Hultman I, Fotouhi O, Marklund S, Ährlund-Richter L, et
al: Loss of miR-514a-3p regulation of PEG3 activates the NF-kappa B
pathway in human testicular germ cell tumors. Cell Death Dis.
8(e2759)2017.PubMed/NCBI View Article : Google Scholar
|
|
152
|
Roška J, Lobo J, Ivovič D, Wachsmannová L,
Mueller T, Henrique R, Jerónimo C, Chovanec M and Jurkovičová D:
Integrated microarray-based data analysis of miRNA expression
profiles: Identification of novel biomarkers of
cisplatin-resistance in testicular germ cell tumours. Int J Mol
Sci. 24(2495)2023.PubMed/NCBI View Article : Google Scholar
|
